

KEY LEVELS

Support 1 : 7890
Resistance 1: 8230

Nifty Intraday Chart



Market Outlook

Indian equities gave a range bound and choppy movement throughout the day on Wednesday and after opening on a subdued note, Nifty moved in the narrow range of 8180 - 8219. At the day the index closed with a marginal loss 1.75 points. The midcap and small cap indices outperformed the benchmark index and closed the day after gaining 0.5%-0.8%.

On the sectoral front, some buying interest was witnessed in Realty, Information Technology and FMCG stocks while Banking and Financial services stocks have shown some weakness. The breadth of the market was positive and about three shares advanced for two shares declined at NSE.

Indian services activity contracted for second month in December and the Nikkei/ Markit Services Purchasing Managers' Index (PMI) came in at 46.8 in December 2016 as against 46.7 in November 2016. The average PMI activity index reading for the October– December quarter was the lowest since early 2014.

The foreign investors were the net sellers in the cash segment and they sold Rs 1178 crores of equities on Wednesday.

Nifty is trading in the range of 7900 and 8300 for almost about 2 months since de-monetization. Next move to trigger around forthcoming budget (1st Feb). Nifty level of 8230 important for near term momentum.

☐

Quote of the Day : "You have to segregate businesses you can understand and reasonably predict from those you don't understand and can't reasonably predict. An example is chewing gum versus software." **Warren Buffett**

Market

Market	Value	% Change
Morning Traded Market		
SGX NIFTY	8,232.00	0.41%
NIKKIE	19573.02	-0.11%
HANG SENG	22,266.85	0.59%
Yesterday Closing Market		
Sensex	26,633.13	-0.04%
Nifty	8,190.50	-1.75%
DOW	19,942.16	0.30%
NASDAQ	5,477.00	0.87%
CAC	4,899.40	0.00%
DAX	11,584.31	0.00%
FTSE	7,189.74	0.16%
EW ALL SHARE	14,818.72	0.07%

% Change in 1 day

Commodity Price (Yesterday Closing)

Commodity/Currencies	Value	% Change
GOLD	27682.00	-0.35%
SILVER	40267.00	-0.01%
CRUDEOIL	53.17	-0.19%
NATURALGAS	221.10	-3.41%
DOLLAR/RS.	68.05	-0.41%
EURO/RS.	71.43	0.34%
POUND/RS.	83.74	0.16%

% Change in 1 day

Institutional Turnover

FII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
04-Jan-17	3428	4229	(801)
Jan-17	2868	3629	(761)
2017	2868	3629	(761)
DII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
04-Jan-17	1887	1460	427
Jan-17	3755	3172	583
2017	3755	3172	583

Event Today

Interim Dividend

KPL : Rs. 6/-
(Exdate : 6.1.2017)

Board Meeting

SASTASUNDR : General
JAGRAN : Buy Back of Shares

CUPID : General

Quarterly Results

GMBREW

Buy Back of Shares

HEXAWARE , SASKEN
(Exdate : 5.1.2017)

IEA Snapshot

M&M

"BUY"

5th Jan 2017

Management believes that the demonetization issue may have short term negative impact on Farm Equipment segment. They expect this concern will last for next 4 months but sticks with previous growth guidance of 20% for tractor industry in FY17. We believe that the tractor industry may not see much slow-down because the monsoon was good during the year and almost 90% of the tractors are financed. New launches in 2HFY18 in Tractor and SUV segments will make the Mahindra's presence further stronger in the domestic market. Ssangyong have also seen recovery on nine month basis and it may post positive results in the current fiscal after three consecutive years of losses. Considering the strong volume growth and recovery in the non-performing business we recommend 'BUY' with a target price of Rs.1600.

MARUTI

"BUY"

3th Jan 2017

We expect current demonetization issue may not be impacting much in the long run to the passenger vehicle segment because more than 75% vehicles are financed. But this issue may be hampering sales in near future due to cash crunch in the economy. We assume volumes in the second half may be down by 10% in comparison to the first half 2017. Higher sales of premium segment cars will further increase the realization per car, which will in turn maintain the margins going ahead despite the rising commodity prices. Hence we have positive view on this stock and we recommend "BUY" with a target price of Rs.6100.

**For details, refer to our daily report- India Equity Analytics*

Top News

- US Food and Drug Administration (USFDA) has issued a warning letter to **Wockhardt's** Ankleshwar plant for data integrity issues, destruction of records and other violation of good manufacturing practices. Three of the company's plants, including the one at Ankleshwar, are under an import alert. In its warning letter FDA said the company failed to take measures to prevent microbiological contamination.

- **KEC International Mgt Guideline** : This year Company have already got railway orders of Rs 1,100 crore and we are L1 in another Rs 400 crore. So hopefully, by this yearend we should close with an order intake of Rs 1,500 crore . Company was lower than the T&D margins. T&D are average between 8 and 10 percent. Railways were slightly lower than that and that is mainly because of the volumes.

- **Power Grid** said the company has projects worth Rs 1 lakh crore in hand and they look forward to investing in the projects in the next 3-4 years. Company said investments of Rs 20,000 has already been completed in this year. Company has projects worth Rs 1 lakh crore and that we have to invest in next 3-4 years. We have already investing approval of Rs 20,000 crore in this year and one by one awarding process is going on. The company is looking forward to bag roughly Rs 10,000-12,000 crore worth of orders in FY17. Company added in totality Rs 25,000 crore worth of orders is up for grabs for FY17.

- **SAIL** said it has produced 10.18 million tonnes of saleable steel in April to December period of the current fiscal, registering a 15 percent growth over the year-ago period.

- **Sun Pharmaceutical Industries Ltd** and includes its subsidiaries or associate companies), announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera™ is a patented, novel, proprietary nanomicellar formulation of cyclosporine A 0.09%. It is a clear, preservative-free, aqueous solution. Seciera™ is being developed by Ocular Technologies, a company recently acquired by Sun Pharma

- **NBCC** said it will issue one bonus share on every two held in the company this fiscal. A total 30 crore bonus shares will issued at a face value of Rs 2 per share, amounting to Rs 60 crore. The bonus shares, to be issued on or before March 3, 2017, will be given from the free reserves created out of the company's profits.



- **India Goods and services tax (GST) Council**, indicating that a roll-out of the new indirect tax regime is difficult not only from April 1, but also from July 1, 2017.

- **British Net consumer** lending beat expectations to jump by 1.926 billion pounds (\$2.36 billion) in November - the biggest monthly rise since March 2005 - and is 10.8 percent higher than a year earlier.



- **Euro zone CPI** rose to a seasonally adjusted annual rate of 1.1%, from 0.6% in the preceding month. Analysts had expected Euro zone CPI to rise to 1.0% last month.

- **The Nikkei/Markit India Services Purchasing Managers'** Index which tracks services sector companies on a monthly basis, stood at 46.8 in December, little changed from November's 46. The seasonally adjusted Nikkei India Composite PMI Output Index — which maps both manufacturing and services sectors — stood at 47.6 in December, from 49.1 in November.

F&O OPEN INTEREST (Number of Contracts)



MARKET MOVERS (1 MONTH CHANGE)



TRADING IDEAS

Scrip	Reco	Initiation Price	Target 1	Target 2	Stop Loss	Rational
OMAXE	Buy	160.95	168	175	154	After getting a strong support near 200 DMA, the stock has given a sharp pullback rally yesterday. In the extreme short term some fresh buying is likely to emerge in the stock from the current level.
BEML Jan 1020 CE	Short (1 lot = 600)	28.7	16	5	40	The stock found a stiff resistance near Rs 1023 and thereafter corrected yesterday. It has also made a negative divergence in Stochastic on daily chart. In the short term it is very unlikely to breach this level.

Economic Calendar					
Country	Monday 2th Jan 17	Tuesday 3th Jan 17	Wednesday 4th Jan 17	Thursday 5th Jan 17	Friday 6th Jan 17
US		Final Manufacturing PMI , ISM Manufacturing PMI , Construction Spending m/m, ISM Manufacturing Prices.	ADP Non-Farm Employment Change, ISM Non-Manufacturing PMI, Crude Oil Inventories, FOMC Meeting Minutes, Total Vehicle Sales.	Challenger Job Cuts y/y , Unemployment Claims , Natural Gas Storage ,	Average Hourly Earnings m/m , Non-Farm Employment Change, Unemployment Rate , Trade Balance , Factory Orders m/m , IBD/TIPP Economic Optimism.
UK/EURO ZONE	German Prelim CPI m/m , Spanish Manufacturing PMI , Italian Manufacturing PMI , German Unemployment Change, German Unemployment Change, Construction PMI, Manufacturing PMI.	German Prelim CPI m/m , French Prelim CPI m/m , German Unemployment Change.	Spanish Unemployment Change , Spanish Services PMI, Italian Services PMI, French Final Services PMI, German Final Services PMI , Services PMI, Net Lending to Individuals m/m, CPI Flash Estimate y/y.	Retail PMI , PPI m/m , French 10- y Bond Auction , ECB Monetary Policy Meeting Accounts.	German Factory Orders m/m , German Retail Sales m/m.
INDIA	Auto no, Nikkei Manufacturing PMI.		Nikkei Services PMI		

DISCLAIMER

This document has been prepared by Microsec Capital Limited (hereinafter referred to as MCL) to provide information about the Company (ies)/ sector(s), if any, covered in the report and may be distributed by it and/or its associates.

This report does not constitute to be any investment, legal or taxation advice. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and MCL is not soliciting any action based upon it. This report should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this report, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. Neither MCL, its subsidiaries/ Associates, nor its directors, employees, agents, representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information/research reports/ opinions expressed herein.

While we would endeavour to update the information herein on reasonable basis, MCL and/or its associates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MCL and/or its associates from doing so. MCL/it's associates or employees shall not in any way be responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MCL/it's associates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MCL and its associates, their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MCL and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report.

The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Subject Company may have been a client of MCL or its associates during twelve months preceding the date of distribution of the research report. MCL or its associates may have investment banking and other business relationships with some companies covered by our Research Department. Any or all of the foregoing among other things, may give rise to real or potential conflicts of interest.

MCL and it's associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. MCL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Microsec Capital Ltd. ("MCL") is SEBI registered Research Analyst under SEBI (Research Analyst) Regulation 2014 having registration Number INH300002407. Besides, MCL is SEBI registered stock broker, Depository Participant, Merchant Banker, Portfolio Management Services, AMFI registered Mutual Fund distributor, Insurance Repository, POP with PFRDA.

The Company issues research reports to clients/prospective clients/others without any additional fees/charge.No material disciplinary action impacting equity research analysis activities has been taken by any statutory/ Regulatory authority against MCL.

Analyst Certification The matter related to the report has been taken from sources believed reliable and the views expressed about the subject or issues in this report accurately reflect the personal views of the analyst/analysts. MCL does not compensate partly or in full, directly or indirectly, related to specific recommendations or views expressed by the research analysts. Disclosure of interest statement of research analyst is as below:

- | | |
|---|-----|
| 1.Analyst's ownership of the stocks mentioned | NIL |
| 2.Served as an officer, director or employee in subject Company | NO |

Office No: 6 , 5th floor Tower- IIInd,
Stellar IT Park Plot No. C -25 , Sector – 62 ,
Noida – 201309 . Delhi NCR Phone : +91-120-4155509
Email: research.insti@microsec.in, Website: www.microsec.in